2 Marijuana Stocks That Are Making Noise in The Biotech Industry


There are two are two sectors that continue to drive the market and when you combine the two together, it’s an investors dream. The biotech sector rallied in 2017 and is poised to benefit greatly this year from President Donald Trump’s tax overhaul. Then there is the marijuana sector that continuously heats up markets around the globe as legalization reaches more states and countries. Combine those two together and it’s a match made in heaven. Here are two companies that are worthy of adding to your watch-list this January.

Cara Therapeutics’ (CARA) stock price has shot up as much as thirty-five percent in the last month. The biotech’s lead candidate, CR845, is in two late-stage studies one for the relief of post-operative pain and the other for treatment of chronic kidney disease-associated pruritus. The company’s drug CR701, a cannabinoid receptor agonist is where it comes into the marijuana sector. Like CR845, the drug is seeking to replace opioids as a primary treatment option for pain.

CR701 intends to do this by using the cannabinoid receptor system in the human body. CR701 has established positive results in rodent studies, but we will wait to see how the company will move this preclinical data into human-based clinical trials. I do want to point out, although it is still in premature stages CR701, a nice portion of Cara’s valuation can be contributed from the budding outlook of marijuana stocks.

GT Biopharma’s (GTBP), who focuses on cannabinoid therapy. Recently the stock price has gone in a different direction in the last month, but I don’t think it makes it any less valuable. This marijuana biotech is continuing its progress with its FDA phase 2 cancer treatment OXS-1550 and is in FDA phase 1 clinical trials for its Myasthenia Gravis Autoimmune muscular disease in which it has completed dosing in early January.

Similarly, the company is using a cannabinoid approach for the treatment in pain to move the market away from opioids. (GTBP) filed their application to list its common stock on the NASDAQ in December and recently announced a financing with Oppenheimer & Co. raising 7.1 Million Dollars at $4.58 per share. With all this upbeat news, it’s inevitable that as the company progresses even further.

MARIJUANASTOCKS.com is owned by MAPH ENTERPRISES LLC., an affiliate of MIDAM Ventures LLC a Florida Corporation that has been compensated $150,000.00 by a GT Biopharma Inc. for a period beginning Jan 1, 2018 and ending Feb. 1, 2018 now extended till March 1, 2018 for an additional $250,000 paid for by GT Biopharma Inc. to publicly disseminate information about (GTBP). We own zero shares.


Please enter your name here
Please enter your comment!